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Sseparated into access site used, and procedural and clinical outcomes were compared.
MACE was reported at 30 days.
Results: 685 patients underwent RA PCI (Radial n ¼ 398 and Femoral n ¼ 287)
during the study period. There was a predominance of male patients in the radial group
(75.4% Vs 63.4% p<0.001) and more likely to have left ventricular impairment
(32.8% Vs 15.4%, p<0.001). No other difference in baseline demographics was seen
between the two groups. Procedural success was identical in both cohorts (98.5 Vs
97.5, p¼0.62) but radial cohort received more drug-eluting stents (91.2% Vs 85.3%,
p¼0.03). Guide catheter size in the radial cohort was smaller (6.55F Vs 6.95F,
p<0.001), average burr size was similar. The femoral group underwent more left
main-stem PCI (14.2% Vs 21.8%, p¼0.01) and additional imaging (23.2% Vs 32.9%,
p¼0.03). The procedural time (76.3 vs 92.6mins, p<0.001) and time to ﬁrst balloon
inﬂation (39 vs 54mins, p<0.001) were signiﬁcantly lower in the radial cohort, as was
mean length of stay (1.43 vs 2.93 days, p¼0.008). Bleeding and vascular access
complications were similar between the two groups as was 30 day MACE (Radial
6.45% vs Femoral 4.08%, p¼0.15).
Conclusions: This is the largest comparison to date of radial versus femoral access
rotablation. Our data demonstrate that radial RA PCI can be performed safely, with
smaller guide catheters and similar procedural success. Procedural time and time to
ﬁrst balloon inﬂation was signiﬁcantly less in the radial cohort, whereas 30-day
MACE rates and access-associated complications were similar between both groups.
Our results show that radial access is safe, effective and perhaps more efﬁcient method
for performing RA.
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Background: Bleeding is a major complication in patients treated for acute coronary
syndromes (ACS) with antithrombotic and invasive strategy. Consequently, the
beneﬁt of such therapies should be balanced against the potential risk of hemorrhagic
complications. CRUSADE and more recently MEHRAN models provide two risk
scores that predict the likelihood of major bleeding in patients hospitalized with ACS.
The aim of this study: was to evaluate the performance of both CRUSADE AND
MEHRAN risk scores to predict in-hospital major bleeding in a contemporary cohort
of patients hospitalized for ACS in One center in Tunisia.
Methods: The study subjects were 278 consecutive patients admitted to our center
between January 2010 and August 2011 with ACS. For each patient, we calculated
both the CRUSADE and MEHRAN risk score and evaluated its discrimination by the
C statistic.
Results: By CRUSADE and MEHRAN risk scores, our patients were classiﬁed as
high or very high risk of major bleeding in 24.8%, 45.7% of cases, respectively. The
overall incidence of in-hospital bleeding events and major bleeding (BARC major
deﬁnition: BARC 3, BARC 4 and BARC 5) was 12.6%, 4.4%, respectively. The
major bleeding rate increased with the CRUSADE risk category: very low 2.3%; low
3%; moderate 3.6%; high 8.1%; and very high 9.4%.There were twice fewer observed
major hemorrhagic events than predict in case of high and very high risk according to
CRUSADE score. A stepwise increase in rates of major bleeding with increasing
MEHRAN score was also noted (low 0%, moderate 4.9%, high 4.4% vs very high
10.2%). The incidence of the major bleeding predicted by MEHRAN is rather close to
that observed in our population. The curve ROC showed a better correlation of the
MEHRAN score (area under the curve 0.76) than the Crusade score (area under the
curve 0.67) with the major bleeding events observed.
Conclusions: Conclusions: In our clinical practice, bleeding is a relatively frequent
non-cardiac complication of contemporary therapy for ACS especially in high risk
patients. The MEHRAN score seems more correlated to the real life of the Tunisian
coronary patients.
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Background: Platelet reactivity (PR) may predict bleeding events after percutaneous
coronary intervention (PCI), which are associated with increased risk of death. Based
on a bleeding risk score (BRS) of clinical and procedural variables (bleedingriskscore.
org), we developed and validated a new prognostic risk score also including PR
(BRS-PR).
Methods: A total of 800 patients receiving clopidogrel and undergoing elective
PCI via the femoral approach were included in this study. PR was measured
immediately before PCI with the VerifyNow P2Y12 Assay. Calculation of the BRS
included the following variables: age, gender, intra aortic balloon pump, glycoprotein
IIb/IIIa inhibitors, chronic kidney disease, anemia, low-molecular-weight heparinB96 JACC Vol 62/18/Suppl B j October 27–Novwithin 48h pre-PCI. Low-platelet reactivity (LPR), deﬁned as a PR value 178
P2Y12 reaction units, was also included in BRS-PR and assigned a weighted
integer based on multivariable model of predictors of Thrombolysis in Myocardial
Infarction (TIMI) bleedings. Bleeding events were monitored up to 30 days
after PCI and deﬁned according to the TIMI, Randomized Evaluation in PCI
Linking Angiomax to Reduced Clinical Events (REPLACE-2) and Bleeding
Academic Research Consortium (BARC) deﬁnitions. BRS-PR was also tested in the
ARMYDA-BLEEDS study population (n¼310) for TIMI bleedings for validation
purpose.
Results: A total of 28 (3.5%) TIMI, 44 (5.5%) BARC class 2 and 32 (4%)
REPLACE-2 bleedings occurred. In the development set, BRS-PR could signiﬁcantly
discriminate between patients with and without bleeding (AUC >0.8 for all bleeding
deﬁnitions). Discriminatory power of BRS-PR was signiﬁcantly better than that of
BRS alone (p<0.001 for all bleeding deﬁnitions). In the validation set, BRS-PR could
signiﬁcantly discriminate between patients with and without TIMI bleeding with an
AUC of 0.788, with a better discriminatory power compared with that of BRS alone
(AUC¼0.709, p¼0.036).
Conclusions: Including PR in a risk score of clinical and procedural variables
improves prediction of bleeding events after PCI via the femoral approach.
TCT-298
Radial versus Femoral Accesses for Percutaneous Coronary Interventions in
Patients with Acute Coronary Syndromes
Elmir Omerovic1, Elmir Omerovic1
1Sahlgrenska University Hospital, Gothenburg, Sweden
Background: The purpose of this observational study was to evaluate the prognostic
effects of radial artery access (RA) versus femoral artery access (FA) in patients
undergoing percutaneous coronary intervention (PCI) due to acute coronary syndrome
i.e. ST-elevation myocardial infarction (STEMI) and unstable angina/non-STEMI
(UA/NSTEMI).
Methods: Data were obtained from the SCAAR registry (Swedish Coronary Angi-
ography and Angioplasty Registry) for PCI procedures performed in Västra Götaland
region in Sweden between 2005-2011. We evaluated 30-days mortality in 10007
patients, N¼4386 in RA and N¼5621 in FA. The two groups were compared using
Cox proportional hazards regression with "shared frailty" to account for hierarchical
database. Adjustments for differences in baseline characteristics were made with
propensity score. The following variables were included in the calculation of the
propensity score: age, gender, indication for PCI, smoking habits, hypertension,
diabetes, hyperlipidaemia, severity of coronary artery disease, previous infarction,
previous PCI, previous coronary artery by-pass surgery (CABG), anticoagulation
therapy with glycoprotein IIb/IIIa receptor antagonists (GP IIb/IIIa), bivalirudin,
clopidogrel, unfractionated heparin/low-molecular weight heparins (UH/LMWH),
year, hospital.
Results: The two groups were balanced regarding age, gender, diabetes, smoking
habits, hypertension and hyperlipidaemia. RA patients were more likely to be pre-
treated with aspirin, clopidogrel and to receive bivalirudin and drug-eluting stents
during the procedure. FA patients were more likely to had previous myocardial
infarction, previous PCI, previous CABG and to receive GP IIb/IIIa and UH/LMWH
during the procedure. There were 3761 patients (37.6%) with STEMI and 6246
(62.4%) with UA/NSTEMI. More patients with STEMI underwent PCI through FA.
RA was associated with 38% reduction in 30-days mortality (1.5% vs. 2.8%; HR 0.62;
95% CI 0.44–0.87; p ¼ 0.005).
Conclusions: In patients with acute coronary syndromes, PCI through radial artery
access is associated with reduced 30-days mortality. A properly designed randomised
clinical trial is urgently needed to test the hypothesis that radial artery access decreases
mortality in patients with acute coronary syndrome.
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Background: Transradial coronary intervention (TRI) is increasingly performed, with
the standard 6 French (Fr) guiding catheters (GC) employed by most operators.
However, based on the radial artery size, only up to 72% of female and 85% of male
Asian patients can physically accept the 6 Fr sheath. The 5 Fr GC reduces patient
discomfort, radial artery spasm and occlusion (RAO), although there is a need to
crossover to the 6 Fr GCs in a small proportion of cases. The novel sheathless (SH)
GCs maintains the advantage of the The aim of this study is to assess the safety and
efﬁcacy of a sheathless (SH) 6.5 Fr hydrophilic-coated guiding catheter (outer
diameter nearly equivalent to a 4F sheath – "virtual 4F guiding catheter") compared to
the standard 5 Fr GCs in TRI.
Methods: Patients undergoing TRI between November 2008 and June 2013 were
included. Baseline characteristics and in-hospital outcomes were recorded. Primary
endpoints were procedural success and presence of radial pulse at discharge.ember 1, 2013 j TCT Abstracts/POSTER/Vascular Access and Closure
